



CAIRD

CONGRESS ON ADVANCES IN
INHERITED RETINAL DISEASES



NOVEMBER

19 – 20, 2026




VALENCIA, SPAIN

CENTRO DE INVESTIGACIÓN
PRÍNCIPE FELIPE

Beyond research: understanding, supporting, and moving forward

A congress created to connect research, professionals and the community, promoting a more humane, participatory and transformative approach to retinal dystrophies.

More info and registration: <https://caird2026.coeves.com/>



VALENCIA BIOMEDICAL
RESEARCH FOUNDATION
CENTRO DE INVESTIGACIÓN PRÍNCIPE FELIPE



ciber | **ER** CENTRO DE INVESTIGACIÓN
BIOMÉDICA EN RED
Enfermedades Raras



CLÍNICA RAHHAL
OFTALMOLOGÍA

Colaboran:



Scharlab
THE LAB SOURCING GROUP



Thursday 19th November – Scientific session

9:00 - 9:30 h

Welcome.

Deborah Burks (Director of CIPF), Javier Copovi (Director General de Discapacidad Ayuntamiento de Valencia), José María Millán (Scientific director of CIBERER), Regina Rodrigo (Group Leader Pathophysiology and Therapies for Vision Disorders, CIPF)

Session 1. European Reference Networks: ERN-EYE and ERDC as Drivers of Innovation and Equity in Rare Diseases.

Session chair: Eduardo Silvas.

9:30 - 10:00 h

Rosa Coco, Ophthalmology Department, Hospital Clínico Universitario de Valladolid, Valladolid, Spain. IOBA. ERN EYE member.

European Reference Network for Rare Eye Diseases (ERN-EYE): "The knowledge travels, not the patient."

10:00 - 10:30 h

Susanne Roosing. ERDC member, Blindness genetics and transcriptomics, Radboudumc, Nijmegen, The Netherlands.

From Networks to Impact: The ERDC Perspective on Innovation and Equity in Rare Diseases.

10:30 - 11:00 h

Coffee Break and Poster Session.



Session 2. Clinical Genetics and Gene Therapy: From Diagnosis to Personalized Intervention.

Session chair: Teresa Diago.

11:00 - 11:45 h

● Carmen Ayuso. Department of Medical Genetics.
Fundación Jiménez Díaz, Madrid, Spain.
Inherited Retinal Dystrophies in Spain. A way of 35 yrs.

11:45 - 12:30 h

● Eduardo Silva, Hospital Dona Estefânia, Lisboa,
Portugal.
*Clinical trials in IRD. Where do we stand and how
may we improve.*

12:30 - 13:00 h

● Cristina Martínez. Nuffield Department of Clinical
Neurosciences, University of Oxford. United Kingdom.
*The RPGR gene therapy journey: lessons from bench
to bedside.*

13:00 - 14:30 h

● Lunch and Poster Session.

Session 3. Pharmacological Strategies in Rare Diseases: Mechanisms, Models, and Preclinical Validation.

Session chair: Cristina Martínez.

14:30 - 15:15 h

● François Paquet-Durand. Institute for
Ophthalmic Research. University of Tübingen,
Germany
*Developing protein kinase G inhibitors and
delivery technology for the treatment of
inherited retinal degeneration.*



15:15 - 16:00 h

● Sheyla Velasco. Pathophysiology and Therapies for Vision Disorders, CIPF, Valencia, Spain
Targeting neuroinflammation for retinitis pigmentosa.

16:00 - 16:45 h

● Javier Ruiz-Ederra. University of the Basque Country (EHU)/ Biogipuzkoa HRI/Miramoon Pharma. Donostia-San Sebastián, Spain
Preclinical validation of MP-004 as a mutation-agnostic therapy for retinal degeneration.

16:45 - 17:15 h

● Coffee Break and Poster Session.

Session 4. Advanced Models and New Technologies for Translational Research.

Session chair: Regina Rodrigo

17:15 - 18:00 h

● Gemma Marfany, Department of Genetics, Microbiology and Statistics, University of Barcelona, Spain.
Exploring precision medicine for CERK-associated inherited retinal dystrophies through in vitro and in vivo approaches

18:00 - 18:45 h

● Idoia Gallego, NanoBioCel, University of Basque Country, UPV, Vitoria-Gasteiz, Spain
From Therapeutic Delivery to Precision Medicine: Emerging Technologies for Inherited Retinal Disease.

Final Remarks.





Friday 20th November – Patient session

9:00 - 9:30 h

Bienvenida

Almudena Amaya (Presidenta RETINA CV), Imelda Fernández (Vice-Presidenta Fundación ONCE Baja Visión), Ignacio Grande Ballesteros (Secretario Autonómico de Servicios Sociales, Familia e Infancia), Enrique Llin (Presidente del Consejo Territorial de la ONCE CV), Gema Mas (Defensora de las Personas con Discapacidad de València).

Sesión 1: De la investigación al paciente

Moderador: Pedro García Recover

9:30 - 10:15 h

José María Millán. Biomedicina Molecular, Celular y Genómica, IIS La Fe, Valencia, España
Resumen de la jornada científica del día anterior dirigida a los pacientes.

Sesión 2: Soluciones para el día a día de un paciente con baja visión.

Moderador: Pedro García Recover.

10:15 - 10:45 h

Andrés Merino, Óptica Burgalesa, Burgos, España.
Soluciones ópticas para pacientes con baja visión.

10:45 - 11:15 h

Pausa café.



11:15 - 12:00 h

Enrique Llin Ruiz, Presidente Consejo Territorial, ONCE Comunidad Valenciana. Representante de Unidad de Seguridad Vial de la Policía local y Representante de Retina CV.
Accesibilidad.

Sesión 3: Más allá del diagnóstico: Mirada psicológica y diálogo médico

Moderador: Pedro García Recover.

12:00 - 12:30 h

Isabel Campillo y Carmen Milla - Psicólogas CIPF y RETINA CV, Valencia, España.
Impacto emocional del diagnóstico de una DHR.

12:30 - 13:00 h

Enrique Rodríguez de la Rúa - Hospital Universitario Virgen Macarena, Sevilla
Diálogos con el especialista.

Organisers

Centro de Investigación Príncipe Felipe
Retina CV
Generalitat Valenciana

Funding Support

Fundación ONCE Baja Visión · Clínica Rahhal

Additional Sponsors

Consum · Scharlab

Scientific Endorsement

With the participation and scientific backing of CIBERER

Activity co-financed by the Generalitat Valenciana, through the Department of Education, Culture and Universities, within the grant program for the organization and dissemination of congresses, conferences, scientific, technological, humanistic, or artistic meetings of an international nature (Grant CIAORG/2026/150).

